Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of amrubicin with cisplatin in advanced non-small cell lung cancer
jRCT1080221989Phase 2
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amrubicin and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Sumitomo Pharma.
02
Drugs
amrubicincisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080221989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221989.